[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know",
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=472c005ec33ae69ed0bbbe16aeab18cbc163f670c8376a52af4d574c77385b0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749159914,
      "headline": "AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know",
      "id": 135066336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=472c005ec33ae69ed0bbbe16aeab18cbc163f670c8376a52af4d574c77385b0a"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks",
    "summary": "Investors have been hit with a great deal of volatility and uncertainty in the markets lately.  Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves more experienced names on Wall Street make.  Take Ken Griffin, a successful money manager and the billionaire CEO of Citadel Advisors, the hedge fund he founded.",
    "url": "https://finnhub.io/api/news?id=1f7c84dcc53bd1e7bb20fa2512a3a0955b6bff53ef92b6edde2db0fda81ad52d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749124800,
      "headline": "Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks",
      "id": 135045954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investors have been hit with a great deal of volatility and uncertainty in the markets lately.  Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves more experienced names on Wall Street make.  Take Ken Griffin, a successful money manager and the billionaire CEO of Citadel Advisors, the hedge fund he founded.",
      "url": "https://finnhub.io/api/news?id=1f7c84dcc53bd1e7bb20fa2512a3a0955b6bff53ef92b6edde2db0fda81ad52d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "While the broader market has struggled with the S&P 500 down 1.8% since December 2024, AbbVie has surged ahead as its stock price has climbed by 6.7% to $188.02 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=3bf84fdd9d0606bc27ae67fb38c4a3a51737d551a42604e7b22d0882b7bdc3a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749096140,
      "headline": "AbbVie (ABBV): Buy, Sell, or Hold Post Q1 Earnings?",
      "id": 135047882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While the broader market has struggled with the S&P 500 down 1.8% since December 2024, AbbVie has surged ahead as its stock price has climbed by 6.7% to $188.02 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=3bf84fdd9d0606bc27ae67fb38c4a3a51737d551a42604e7b22d0882b7bdc3a7"
    }
  }
]